Page 3 - Quotient Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Quotient science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Quotient Science Today - Breaking & Trending Today

Nanoform's Clinical Study Indicates Positive Interim Results


Nanoform s Clinical Study Indicates Positive Interim Results
News provided by
Share this article
Share this article
HELSINKI, Jan. 22, 2021 /PRNewswire/ Nanoform Finland Plc ( Nanoform ), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful.
Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the Pharmacokinetic (PK) Profile of Piroxicam following Administration of Nanoformed Oral Immediate Release (IR) Piroxicam Tablet and an IR Reference Product in Healthy Subjects (UNICORN). These interim results are based on the first cohort of twelve healthy volunteers dosed in December 2020 at Quotient Sciences facilities in Nottingham, UK. Final results of the study are expected before the end of Q2 2021, as previously ....

Eteläuomen Läi , United Kingdom , Prnewswire Nanoform Finland Plc , Danske Bank , Finnish Financial Supervisory Authority , Finland Branch , Finland Plc , Part Crossover , Partially Randomised Study Designed , Nanoformed Oral Immediate Release , Piroxicam Tablet , Healthy Subjects , Quotient Science , Nasdaq First North Growth Market , Certified Adviser , ஒன்றுபட்டது கிஂக்டம் , பின்னிஷ் நிதி மேற்பார்வை அதிகாரம் , பின்லாந்து கிளை , பின்லாந்து ப்ல் , பகுதி குறுக்குவழி , ஆரோக்கியமான பாடங்கள் , மேற்கோள் அறிவியல் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ,

First dosing of nanoformed drug successfully accomplished


First dosing of nanoformed drug successfully accomplished
Nanoform
Press Release
First dosing of nanoformed drug successfully accomplished
Helsinki, Finland – Nanoform Finland Plc (“
Nanoform”), an innovative nanoparticle medicine enabling company, today announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s proprietary CESS
® technology. Results are expected before the end of Q2/2021.
Nanoform has now achieved all its near-term business targets for 2020 and 2021 announced in relation to the IPO. New near-term business targets, in addition to the previously (November 27th) announced “First Biologics PoC project in 2021”, will be communicated in the coming months. ....

Eteläuomen Läi , United Kingdom , Mark Egerton , Biologics Po , Danske Bank , Finnish Financial Supervisory Authority , Quotient Sciences , Nanoform Finland Plc , Finland Branch , Quotient Science , Biologics Poc , Nasdaq First North Growth Market , Certified Adviser , ஒன்றுபட்டது கிஂக்டம் , குறி எகர்‌டந் , உயிரியல் போ , பின்னிஷ் நிதி மேற்பார்வை அதிகாரம் , மேற்கோள் அறிவியல் , பின்லாந்து கிளை , உயிரியல் பாக் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ,